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Monoamine neurotransmitter transporters are membrane proteins 
responsible for the clearing of biogenic amines from a synapse. These 
transporters are targets for many important pharmaceuticals including 
antidepressants, as well as psychostimulant drugs such as cocaine and 
amphetamines. Amphetamines are believed to elicit their psychostimulant activity 
primarily by inducing a reversal of the transport cycle and increasing 
neurotransmitter release into the synapse, though the mechanism of this activity 
is incompletely understood. Previous in vitro research has suggested functional 
significance of a conserved salt bridge in the serotonin transporter (SERT) in 
amphetamine-induced 5-HT efflux. This salt bridge is disrupted in the Drosophila 
melanogaster SERT.  Here, a mutant line of D. melanogaster expressing a SERT 
with a restored salt bridge (dSERT N484D) was studied. Changes in 
neurochemistry induced by methamphetamine (METH) or 3, 4-
methylenedioxymethamphetamine (MDMA) were examined in vivo. HPLC/Mass 
spectrometry was used to quantify brain concentrations of neurotransmitters in fly 
tissue after drug treatment. N484D flies were found to have significantly depleted 
vi 
  
5-HT in response to 0.05% MDMA relative to wild-type. This depletion of 
5-HT was not observed after treatment with 0.6% MDMA or 0.6% METH. No 
significant drug-induced changes were observed in concentrations of other 
neurotransmitters examined. The results show that the presence of the salt 
bridge at the external gate of SERT may be important for amphetamine-induced 
5-HT efflux, and helps explain pharmacological differences observed between 



















CHAPTER 1.  INTRODUCTION 
1.1 History of MDMA and methamphetamine 
 MDMA 
MDMA (N-methyl-1-(3, 4-methylenedioxyphenyl)-propan-2-amine), also 
known as ecstasy, is a psychostimulant drug that induces powerful psychoactive 
experiences in humans (figure 1.1). MDMA was first synthesized in 1912 by the 
Merck Corporation as an intermediary product intended for the synthesis of 3-
methyl-hydrastinine, an anti-hemorrhagic drug. Merck patented MDMA as a part 
of this reaction, though no application of the patent was ever utilized by the 
company.1 Years after its discovery the psychoactive properties of MDMA 
became better known. MDMA shares both structural and psychoactive 
commonalities with psychostimulant drugs such as methamphetamine, as well as 
psychedelics such as mescaline and LSD.2 The subjective experience of MDMA 
use includes feelings of euphoria, stimulation, a sense of wellbeing, 
communicativeness, and visual hallucinations.3 Drugs that produce subjective 
experiences of this sort are considered to be members of a unique group, and 
the special term “entactogen” has been conceived to describe and classify them.4  
Recreational use of MDMA first rose in popularity during the 1960s and 




had become a staple drug used at night clubs and rave parties. The stimulant 
effects of MDMA suppress a person’s perception of the need to consume food or 
water. Consequently, MDMA use—particularly in the context of all-night dance 
parties—earned repute for risk of injury or death by dehydration.5  
During the 1970s and early 1980s, MDMA found medical application as an 
adjunct to psychotherapy in individuals suffering from depression and post-
traumatic stress disorder.1, 4 More recently, interest in use for such applications 
has reemerged.6  However, earlier research had suggested that the MDMA 
metabolite MDA is toxic to humans, and other investigations pointed to the high 
likelihood that the MDMA being consumed as a street drug was often 
dangerously impure. Based on this, in 1984, the Drug Enforcement Agency of the 
United States classified it as a schedule 1 controlled substance. Schedule 1 
classification indicates that a drug has a high abuse potential, without any 
accepted medical value and, as a result, medical use of MDMA was promptly 
halted. This scheduling came as a consequence of the DEA being given 
emergency drug scheduling authority. Despite this classification being contested 
as inappropriate for MDMA by psychiatrists, researchers, and courts,7, 8 this 
regulatory status was ultimately upheld in the United States in 1988, after a four 
year legal battle.9 Subsequent studies have shown that MDMA does cause an 
acute neurodegeneration of serotonergic neurons.4, 10 However, debate still 
persists in the medical community regarding the mechanisms by, and, extent to 






 Methamphetamine (N-methyl-1-phenylpropan-2-amine) is a powerful 
stimulant drug with great potential for abuse and addiction (figure 1.1).15 
Methamphetamine (METH) use induces feelings of euphoria, intense arousal, 
increased libido, and reduced appetite and fatigue. 5, 16, 17 A structural derivative 
of amphetamine, METH  was first synthesized from ephedrine in 1919 by 
Japanese pharmacologist Nagai Nagayoshi.16 In subsequent years the drug was 
used medically for its appetite-suppressing and wakefulness-promoting effects. 
As the potential for addiction became better known, METH was classified as a 
schedule 2 controlled substance in the United States in 1970. Today, legal efforts 
have reduced the availability of chemical precursors commonly used for METH 
production (most notably pseudoephedrine), yet the drug is still extensively 
produced and abused illegally. The quality and purity of illicitly-produced METH 
varies widely, and the side effects of potential contaminants are unknown.16 
Despite its notoriety for addiction, METH has accepted medical indications for the 
treatment of exogenous obesity and attention deficit disorder with hyperactivity. 
When used for these purposes it is marketed under the brand name Desoxyn.16, 
18 
 METH use, and particularly chronic use, is associated with numerous 
health deficits, including cardiomyopathy, psychosis, degradation of teeth and 
enamel, depression, sleep disturbances, reproductive dysfunction, oxidative 
stress and abnormal metabolism.11, 15, 17, 19 Amphetamines are used around the 




global phenomenon, with approximately 17.2 million people dependent as of 











1.2 The serotonin transporter  
Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter responsible for 
many biological functions including regulation of sleep, libido, appetite, and 
memory. 5-HT signaling is governed by several systems including ion channels, 
pre and post-synaptic receptors, biosynthetic enzymes, and transporters.21 
 The serotonin transporter (SERT) is a pre-synaptic membrane protein. 
SERT is a member of the solute carrier 6 (SLC6) family of transporters, and is 
responsible for the clearing of 5-HT from the synaptic cleft, thereby terminating 5-
HT neurotransmission.22,23, 24 SLC6 transporters are 12-transmembrane alpha-
helical membrane proteins. They are neurotransmitter-sodium symporters 
(NSSs), which couple the “downhill” transport of sodium to the “uphill” transport 
A. MDMA B. METH 
 
 





of their substrate. This family includes the monoamine transporters SERT, the 
dopamine transporter (DAT), the norepinephrine transporter (NET), three GABA 
transporter (GATs), 2 glycine transporters (GLYs), and a subset of amino acid 
transporters.24 
During normal neurotransmission, neurotransmitters such as dopamine 
(DA), norepinephrine (NE), and 5-HT are released from pre-synaptic neurons into 
the synapses via vesicles. These particular neurotransmitters are monoamines, 
and are known to play an important role in normal rewarding and reinforcing 
behaviors. However, drugs of abuse utilize these same neurotransmitter systems, 
leading to their addictive potential.25  
 Upon being released, these neurotransmitters can bind to their target 
receptors on post-synaptic neurons, thereby propagating a chemical signal. After 
a neurotransmitter has been released into a synapse and has transmitted its 
chemical signal, it is brought back into a pre-synaptic cell via a transporter. Once 
inside a cell, a monoamine neurotransmitter is either broken down by a 
monoamine oxidase (MAO) or repackaged into a vesicle by the vesicular 
monoamine transporter (VMAT) for subsequent reuse.23 (Figure 2A) 
SERT is an important target for many pharmaceuticals, including most 
antidepressants, as well as notable drugs of abuse such as cocaine, and 
amphetamines.26 As serotonin is critically involved in the regulation of mood, 
arousal, appetite, and libido, it naturally became the subject of research in the 
treatment of depression and anxiety disorders.27 During the 1960s the 




inhibiting effects. This observation led to a search for structural derivatives of 
diphenhydramine that would have more specific effects on SERT. This search 
culminated in a class of drugs that would come to be known as selective 
serotonin reuptake inhibitors (SSRIs). SSRIs include antidepressants such as 
sertraline and fluoxetine, which are now some of the most prescribed 
pharmaceuticals.28 Eli Lilly developed the drug fluoxetine during the 1970s, which 
was brought to market in the United States in 1987, and marketed under the 
brand name Prozac.27 Much progress has been made in understanding the 
mechanisms of antidepressant pharmacology in the decades following their initial 
discovery.29 Unipolar depression is an extremely debilitating mental illness, and 
is currently increasing in prevalence globally. It has been projected that by 2020 
unipolar depression will be the second most burdensome disease behind 
ischemic heart attack.20, 30 It is likely that as rates of mental illnesses diagnosed 
increase, use of SSRIs will increase as well. Thus, it is important to continue to 
study the targets of these drugs to increase understanding of their pharmacology, 
and improve available medication therapies.  
 
1.3 Amphetamine action on monoamine systems 
Molecular pharmacology of psychostimulants 
Amphetamines exert their action by being transported into presynaptic 
neurons and inducing a reversal of the transport cycle of the biogenic amine 
transporters. Primary targets are SERT, DAT, NET, and VMAT. By doing so, 




are weak bases, amphetamines also disrupt the proton gradient required for 
normal vesicular uptake, further contributing to altered transport. This mechanism 
of action is unique among psychostimulants. In contrast, the action of cocaine is 
mediated by its binding to the substrate-binding site of monoamine transporters, 
competitively inhibiting the reuptake of monoamines.32, 33 This unique mechanism 
of amphetamine action is incompletely understood, and this research aims, in 
part, to further elucidate this process. 
Monoamine transporters are principal targets for amphetamines. SERT is 
the primary molecular target for MDMA, although MDMA also acts on DAT, likely 
contributing to the subjective experience of the drug.34 In addition to inducing 
neurotransmitter release through effects on transporters, MDMA may also 
interact with biogenic amine receptors, further contributing to its mechanism of 
action.19, 31 METH acts on monoamine amine transporters as well, but is much 
less selective for SERT than MDMA, and has considerably greater affinity for 
DAT and NET. METH induces the release of NE twice as much as it does DA, 
and sixty times more than it does 5-HT.19, 35 Additionally, MDMA and METH are 
both agonists of the trace amine associated receptor (TAAR1). Activation of 
TAAR1 by its native ligands is associated with excitation of the sympathetic 
nervous system. 36 Agonism of TAAR1 by amphetamines has similar effects, and 
also increases DAT efflux and transporter internalization. 37 Amphetamines are 
able to induce their effects on numerous pathways, primarily through action on 
monoamine systems, and especially catecholamine and 5-HT transporters. 




and activity on trace amine systems also contributes to their effects.37 The 
structures of monoamine neurotransmitters pertinent to this research, as well as 
a brief overview of their principal functions can be found in table A.1. 
 
 
Figure 1.2 Normal transporter function. Neurotransmitters are released from 
presynaptic neurons via vesicles into the synaptic space to transmit a chemical 
signal by activating receptors on post-synaptic neurons and glia. Transporters 
clear neurotransmitters from the synapse to terminate signaling. 
Neurotransmitters can then be repackaged into vesicles by VMAT for subsequent 
reuse, or broken down by MAO. 
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Figure 1.3 Amphetamine action on monoamine transporters. Amphetamines 
reverse the flow of neurotransmitters through transporters and inhibit 
neurotransmitter uptake. Neurotransmitters are pumped out of vesicles into the 
cytoplasm where transporters then mediate efflux, thereby increasing synaptic 
concentration of neurotransmitters and receptor activation. 
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1.4 Current problem 
SERT and the external gate 
A crystal structure of SERT has not been resolved, but inferences made 
from the crystal structure of the leucine transporter (LeuT), a bacterial homologue 
of Na/Cl-dependent neurotransmitter transporters (including SERT) from Aquifex 
aeolicus revealed a number of important characteristics of transporter 
architecture.38 Of note, it revealed the presence of internal and external gates in 
the transporter that help to govern the transport cycle by regulating access to the 
substrate binding site. This allows for regulation of transport from either side of 
the membrane. More recently, a structure of the D. melanogaster dopamine 
transporter (dDAT) has been reported,39 as well as mutational variants of LeuT, 
in which residues involved in ligand recognition and transporter function have 
been altered to their corresponding residues in mammalian biogenic amine 
transporters.40, 41, 42 This structural data has illuminated much about the 
mechanics of transport, and factors determining substrate binding. Additionally, it 
has been instrumental in developing a homology model of hSERT.43 
The external gate of NSSs, based on the crystal structure of LeuT, 
contains a pair of amino acids that are able to form a salt bridge between two 
transmembrane helices.38 Amino acid sequence alignment of transporters from 
several species revealed the absence of one of these critical external gating 
residues in dSERT. (Figure 2.3) Additionally, dSERT shows greatly reduced 5-




the hypothesis that the lack of this conserved residue contributes to the variation 
in amphetamine-induced efflux between hSERT and dSERT.  
As previously stated, the primary target for amphetamines are biogenic 
amine transporters. MDMA and other ring-substituted amphetamines exhibit a 
particularly selective affinity for SERT due to the substitutions at the 3 and 4 
positions of the phenyl ring.45 The selectivity of MDMA for the serotonin 
transporter, and the resulting increasing in synaptic concentrations of serotonin, 
is considered to be a significant factor in the unique “entactogenic” quality of the 
drug.46 Additionally, this selectivity for SERT is thought to be partially responsible 
for the reduced addictive potential of MDMA relative to other stimulant drugs. For 
example, METH and cocaine are considered much more addictive than MDMA 
owing to their capacity to increase synaptic DA concentrations by acting on DAT. 
This activation of the DA system is an important factor in the addictive potential 
of these drugs. However, the role of DA in the action of MDMA should not be 
overlooked, as it also plays some role in the effects of MDMA.34 
The exact mechanism for how amphetamines are able to induce reverse 
transport is unclear, although mechanisms relating to phosphorylation of the N-
terminus, as well as structural alterations induced by changes in pH gradient 
have been proposed.47, 48, 49 Understanding the role of this salt bridge may help 
to explain how amphetamines are able to induce reverse transport. Additionally, 
by studying systems-scale drug effects, this work could lead to development of 
novel treatments for amphetamine abusers through improved understanding of 





Figure 1.4 Model of the interaction of the residues forming the salt bridge in 
monoamine transporters. This shows the amino acids forming the salt bridge in 
the external gate of LeuT, consisting of R30 and D404. In hSERT the 
homologous residues are R104 and D484, and in dSERT they are R99 and N484. 














dSERT and hSERT 
The amino acid sequences of the human serotonin transporter (hSERT)  
and D. melanogaster serotonin transporter (dSERT) are approximately 51% 
identical.50 This sequence similarity corresponds to similarities in 5-HT 
recognition and uptake of 5-HT between the D. melanogaster and mammalian 
transporters. However, differences in transport of amphetamines and other 
substrates between the hSERT and dSERT have been observed.51, 44 Previous 
research in the Barker lab has identified a key region of SERT that appears to be 
important in the molecular mechanisms of amphetamine activity. Sequence 
alignment of NSSs shows a highly conserved salt bridge in the extracellular 
vestibule of transporters across numerous species that is lacking in dSERT 
(figure 4). dSERT is unique amongst transporters of other species examined in 
that this acidic residue is highly conserved, but is a basic residue in D. 
melanogaster.  The salt bridge in hSERT is composed of Arginine 104 and 
Glutamate 493. The homologous residues in the dSERT are Arginine 99 and 
Asparagine 484. Generally, a salt bridge has a stabilizing effect on protein 
structure, reducing conformational flexibility.52 The salt bridge found in 
monoamine transporters is hypothesized to have such an effect, aiding in the 
tight closing of the transporter and preventing the leak of neurotransmitters out of 
the cell.  
Additional in vitro assays were previously performed in the Barker lab 
utilizing HEK-293 cells transfected with SERT salt bridge mutants. These 





Figure 1.5 Transporter sequence alignment. An acidic residue (aspartate or 
glutamate, E or D) is highly conserved across monoamine transporters from 
several species, but is replaced by an asparagine (N) in dSERT (bold). All 
sequences obtained from www.Uniprot.org. 
 
  
hSERT 101 N V W R F P Y 107 … 489 K L L E E Y A 496
dSERT 96 N V W R F P Y 102 … 481 N F L N V Y G 487
LeuT 27 N F L R F P V 33 … 401 D E M D F W A 407
mSERT 101 N I W R F P Y 107 … 489 T L L E E Y A 495
rSERT 101 N I W R F P Y 107 … 489 T L L E E Y A 495
bSERT 101 N V W R F P Y 107 … 489 K L L E E F A 495
gpSERT 101 N I W R F P Y 107 … 489 K L L E E Y A 495
hDAT 82 N V W R F P Y 88 … 473 T L L D H F A 479
dDAT 49 N V W R F P Y 55 … 472 H L L D R Y A 478
mDAT 82 N V W R F P Y 88 … 472 T L L D H F A 478
rDAT 82 N V W R F P Y 88 … 472 T L L D H F A 478
hNET 79 N V W R F P Y 85 … 469 T L L D T F A 475
mNET 78 N V W R F P Y 106 … 470 T L L D T F A 476
rNET 78 N V W R F P Y 84 … 470 T L L D T F A 476
mGAT 54 N V W R F P Y 60 … 444 Q L F D Y Y A 450




and changed hSERT to the dSERT equivalent (E493N). These experiments 
revealed numerous differences between hSERT and dSERT: dSERT exhibits 
basal efflux of 5-HT that does not occur in hSERT. This is hypothesized to be a 
consequence of the absence of the salt bridge, which likely helps to keep hSERT 
closed more tightly, preventing 5-HT leak. 
Amphetamine-induced efflux is greatly reduced in dSERT relative to 
hSERT. Electrophysiology experiments showed that amphetamines are 
substrates for hSERT, but not dSERT.51 The N484D mutation in dSERT was able 
to restore amphetamine-induced currents to levels comparable to hSERT in 
response to MDMA  
The lack of a salt bridge likely accounts for some differences in 
pharmacology observed between hSERT and dSERT.51 Altering amino acid 
residues in dSERT to the corresponding residues in hSERT can make dSERT 
pharmacology more like that of hSERT.53 A mutant line of D. melanogaster 
(N484D) containing this salt bridge is currently being investigated in vivo. This 
line of flies is not a knockout mutant, and contains both wild-type dSERT and 
dSERT N484D. 
Current Problem 
 The goal of this project was to investigate the role of a salt bridge at the 
external gate of the SERT in MDMA/METH-induced neurotransmitter efflux in 
vivo. 5-HT efflux is believed to be a major component underlying the effects of 
these drugs. Previous in-vitro studies in our lab identified reduced amphetamine-




hypothesized to be due to the lack of this highly conserved salt bridge in D. 
melanogaster. 
To further investigate this problem in vivo a mutant SERT has been 
generated and inserted into D. melanogaster which contains a mutation (N484D) 
that restores this salt bridge. It is hypothesized that this dSERT mutation will 
facilitate tighter closing of the external gate, and thus restore the amphetamine-
induced efflux found in hSERT. 
Significance of the Problem 
The mechanisms underlying amphetamine-induced efflux are poorly 
understood.54 Previous work has demonstrated that single amino acid changes in 
SERT in different species are able to alter ligand binding and pharmacological 
activity.53, 55, 56 
In vivo experiments may reveal how this residue is able to influence 
MDMA activity and amphetamine-induced changes in neurochemistry. Previous 
cell based assays demonstrated the importance of this residue in in vitro drug-
activity, and this work corroborates those assays using an in vivo model. 
Additionally, D. melanogaster has previously been used to study genomic, 
proteomic, and transcriptomic changes after exposure to METH.15 This model 
could also be extended to MDMA to observe systems-level changes resulting 
from MDMA-induced 5-HT depletion in N484D flies in efforts to discover new 









CHAPTER 2.  AMPHETAMINE PHARMACOLOGY IN D. MELANOGASTER 
2.1 Use of D. melanogaster as a model system 
Rationale for the use of D. melanogaster 
Previous research in the Barker lab utilizing in vitro assays demonstrated 
important pharmacological differences between dSERT and hSERT. Specifically, 
it was observed that hSERT will readily efflux when exposed to amphetamines, 
however dSERT has minimal response to amphetamines.51 As the conserved 
acidic residue present in most monoamine transporters is an asparagine in 
dSERT, an important role may exist for this residue in mediating MDMA/METH 
action on SERT. Indeed, previous research in the lab, as described above, 
confirmed that this gating residue plays a key role in the differences between 
hSERT and dSERT in amphetamine-induced efflux. 
To further understand the role of this residue, the fruit fly, D. melanogaster 
was used for the study of drug action in vivo. D. melanogaster is a very suitable 
and ubiquitous model organism in part because of the relative ease of husbandry, 
and its well-characterized genome. Additionally, useful inferences about other 
animals can be made from evaluating genetic manipulations in the fly, owing to 
the high degree of homology between the two genomes.57 Capitalizing on this 




with human diseases have been found to be shared between humans and D. 
melanogaster.58 Thus, using the fly for in vivo studies such as those performed 
here is worthwhile and convenient. 
Previous research has shown that METH produces behavioral changes in D. 
melanogaster that are very similar to those observed in humans (e.g. increased 
locomotion, reduced food intake, altered metabolism), making D. melanogaster 
an appropriate organism for use in studying amphetamine pharmacology.59, 60 
Inferences made from the impact of amphetamines in D. melanogaster can be 
extended to humans as well, and are likely to assist in the development of 
therapeutics to fight addiction and reduce amphetamine toxicity. For example, 
METH has been found to alter carbohydrate metabolism in D. melanogaster and 
this is believed to contribute to its toxicity.15 Experiments already performed have 
revealed that increased dietary trehalose was able to significantly reduce METH 
toxicity by attenuating a METH-induced Warburg-like effect in D. melanogaster.15, 
59 Thus, further systems-scale studies hold promise to reveal additional pathways 
contributing to amphetamine toxicity and its treatment. 
D. melanogaster husbandry and drug administration 
 Wild-type (w1118 strain) and dSERT N484D mutant flies were received 
from collaborator Dr. Barry Pittendrigh (University of Illinois at Urbana-
Champaign). Flies were reared on the Formula 4-24® Drosophila diet (Carolina 
Biological Supply, Burlington, NC) at 22-23 C and 60-70% humidity.  A targeted 
gene expression system under the control of TrH-GAL4 (tryptophan hydroxylase) 




containing holes for gas exchange and a single cotton swab by which food and 
drugs were administered. Immediately upon arrival a fresh solution of 10% 
sucrose was prepared as food for the flies. Control flies were given 150 µL of the 
sucrose solution, and the experimental group was given 150 µL of sucrose 
containing either MDMA or METH. A red dye was added to provide a means of 
confirming consumption of food and drugs by visual observation of the presence 
of a red pigment in the abdomen. Drug concentrations were 0.6% for METH, and 
either 0.05% or 0.6% for MDMA. Both wild-type w1118, and transgenic flies 
containing the N484D mutant serotonin transporter were used. Each group of 
flies was then exposed to sucrose alone or sucrose with drug for different 
duration of time, ranging from 2 hours to 48 hours. After the appropriate time had 
passed, the experiment was terminated by promptly placing the vials of flies in a -
80˚C freezer.  
 
2.2 Isolation of D. melanogaster brain tissue 
To examine changes in neurochemistry, flies were kept cold on dry ice and 
were decapitated under a microscope. Males were separated from females in 
order to observe potential sex-specific drug effects. Only the fly heads were used 
for further analysis, and all other tissue was discarded, so as to measure only 
changes in brain neurochemistry specifically. 
 Flies from each group were kept separately and prepared for analysis by 
high-performance liquid chromatography coupled to tandem mass spectroscopy 




HT) internal standard was added to a 1.5mL Eppendorf tube containing 
approximately 15 heads for each sample. Samples were kept cold and 
homogenized using a Polytron homogenizer. After homogenization each sample 
was sonicated for 60 seconds, and then stored in a -80˚C freezer until analysis 
by HPLC-MS/MS. 
 
2.3 Mass spectrometry 
HPLC-MS/MS was used to identify and quantify biogenic amine 
concentrations in each sample. This technique is useful because it is highly 
sensitive and is able to detect very small concentrations of molecules of interest. 
The technique has previously been used with success by the Barker lab.61 HPLC 
separates molecules by size by forcing a sample through a column under high 
pressure.  
In these experiments, an internal standard of deuterated 5-HT was used for 
calibration of the HPLC-MS/MS instrument, serving as a constant to quantify the 
concentrations of the monoamines being analyzed in each sample. This is an 
appropriate internal standard because it is similar, but not identical, to each of the 
other biogenic amines being studied. 
Samples were analyzed at Bindley Biosciences Center, Purdue University. 
The instrument employed was an Agilent 1200 HPLC pump and an Agilent 6460 
triple quadrupole mass spectrometer.  The chromatography utilized a Waters 
Atlantis T3 polar amide C18 HPLC column with a mobile phase of a 




22 minutes with an elution time of 3.8 minutes for 5-HT.  The mass spectrometer 
source used a positive polarity electrospray ionization process. The MRM 
transitions were 177.1 to 160.1 for 5-HT and 181.1 to 164.1 for d4-5-HT.
 
2.4 Changes in neurochemistry 
Using an in vivo model allows for the assessment of changes in many 
systems, as opposed to previous in vitro work, which only examined changes in 
SERT activity, specifically. Concentrations of five biogenic amine 
neurotransmitters, 5-HT, DA, octopamine (OCT), NE, and tyramine (TYR) were 
measured to assess for MDMA or METH-induced changes in neurochemistry in 
wild-type and N484D mutant flies in vivo. Changes in concentration were 
analyzed for each neurotransmitter in wild-type vs. dSERT N484D flies, drug-
treated or untreated, and male vs. female. 
 
2.4.1 5-HT results 
5-HT is a neurotransmitter synthesized from the amino acid tryptophan. It 
is involved in numerous core biological functions, including regulation of sleep 
and wakefulness, appetite, and mood.62, 63 As it is the native substrate for SERT, 
as well as a principal target for amphetamines, it was crucial to assess for 
amphetamine-induced changes in levels of 5-HT. Previous in vitro data suggest 
that dSERT is insensitive to MDMA.51 The N484D point mutation is proposed to 
restore sensitivity to MDMA. Flies expressing dSERT N484D were therefore 




indeed this was observed.  The concentration of 5-HT was significantly reduced 
in N484D flies relative to wild type when flies were treated with 0.05% MDMA 
(figure 2.1 A, B, 2.2 A). Post-hoc analysis by multiple t-test using the Holm-
Sidak method revealed that 0.05% MDMA significantly reduced 5-HT in N484D 
flies at 6 and 24 hours. The effects were not yet observable after 2 hours, and 
were no longer observed after 30 hours. Treatment with 0.6% MDMA produced 
direct drug effects in both wild-type and N484D flies (figure 2.1 C, D), but did 
not result in significant differences between the two (figure 2.2, B). METH 
exposure produced direct drug effects in WT flies on 5-HT levels only at the 6 
hour time point (figure 2.1 E), and no differences were observed between wild-














Figure 2.1 Direct Drug Effects on 5-HT concentrations in wild type and N484D 
mutant flies. One sample t-test with a theoretical mean of 1.0 was performed to 
assess for changes in neurotransmitter concentrations between drug-treated and 
untreated flies to assess for drug response. No significant effects were observed 
in Control Flies treated with 0.05% MDMA (Panel A). Significance was reached at 
the 2 hour and 6 hour time points, P=0.0047 and 0.0479, respectively, for N484D 
flies. Effects were present, but did not reach statistical significance by the 24 
hour point, P=0.0640 (Panel B). Significant drug effects were also observed at all 
times measured in wild-type flies treated with 0.6% MDMA, P ˂ 0.01, and at the 2 
hour and 6 hour time points in N484D flies, P=0.0007 and 0.0262, respectively, 
though they were also not observed by the 24 time point (Panels C and D). In 
flies treated with 0.6% METH significant direct drug effects were reached only at 
the 6 hour point in wild-type flies, P=0.0319 (Panels E and F). One sample was 
measured as approximately 30 flies for each drug treatment at each time point. 















































































Figure 2.2 Comparison of 5-HT concentrations in wild-type and N484D flies.  
Two-Way ANOVA showed significantly reduced 5-HT levels in N484D flies 
relative to wild-type after treatment with 0.05% MDMA, P= 0.0039 Post-hoc 
analysis by multiple t-test using the Holm-Sidak method revealed that 5-HT was 
reduced in N484D flies after 6 and 24 hours, P=0.02181 and 0.02536, 
respectively (Panel A). Significant differences were not observed with 0.6% 
MDMA treatment. (Panel B) Two-Way ANOVA failed to show a significant 
reduction in 5-HT levels in N484D flies relative to wild-type after 0.6% METH 

























































































































































2.4.2 Results for Dopamine 
DA is a neurotransmitter derived from the amino acid tyrosine. DA is the 
neurotransmitter most commonly associated with the reinforcing properties of 
addictive psychoactive substances, and is also involved in the coordination of 
movement, reward, attention, memory, and motivation.64 
Based on existing dating that amphetamines induce DA release, 
amphetamine exposure was predicted to reduce concentrations of DA in fly 
tissue samples. Drug-effects were observed in flies treated with 0.05% MDMA at 
two time points, and at one time point in METH-treated flies (figure 2.3). Two-
Way ANOVA showed significantly reduced DA levels in N484D flies relative to 
wild-type, P=0.0262 (figure 2.4 A). However, no differences were observed in 














Figure 2.3 Direct Drug Effects on DA concentrations in wild type and N484D 
mutant flies. One sample t-test with a theoretical mean of 1.0 was performed to 
assess for neurotransmitter concentrations between drug-treated and untreated 
flies. No significant effects were observed in Control or N484D flies treated with 
0.05% MDMA (Panels A and B). In wild-type flies treated with 0.6% MDMA, 
significant drug effects were observed at the 6 and 24 hour time points P=0.0198 
and 0.030, respectively. No effects were observed in N484D flies (Panels C and 
D). In flies treated with 0.6% METH significant direct drug effects were reached 
only at the 6 hour point in wild-type flies, P=0.0134, but not in N484D flies 
(Panels E and F). One sample was measured as approximately 30 flies for each 
drug treatment at each time point. Error bars represent the mean ± SEM of 



































































Figure 2.4 Comparison of DA concentrations in wild-type and N484D flies.  Two-
Way ANOVA showed significantly reduced DA levels in N484D flies relative to 
wild-type after 0.05%MDMA treatment, P=0.0262 (Panel A). However, no 
differences were observed in flies treated with 0.6% MDMA (P = 0.7548) or with 




































































2.4.3 Norepinephrine, tyramine, octopamine, and gender results 
It is well established that MDMA and METH have effects on the 5-HT, DA, 
and NE systems in humans. As such, it was natural to study these 
neurotransmitters. In mammals, NE Influences sleep, wakefulness, attention, and 
feeding behavior.65 Although it is the key neurotransmitter in the sympathetic 
nervous system in humans, NE is not present in D. melanogaster. In invertebrate 
species, NE is functionally replaced by OCT. NE concentration was still analyzed 
by HPLC/mass spectroscopy as a control assessing for contamination. In 
mammals, NE is the principal neurotransmitter governing the sympathetic 
nervous system. Found only in trace amounts, little is known about the function 
of OCT in humans.66 In invertebrates, OCT is present in very high concentrations, 
and is believed to be the principal invertebrate neurotransmitter67, making it 
important to study changes in OCT levels in D. melanogaster. However, results 
from this work found OCT in only very low concentrations, sometimes 
undetectable by HPLC-MS/MS. Consequently, no drug effects, or differences 
between wild-type or N484D flies were observed. 
Additionally, interest in the trace amine tyramine (TYR) as a catecholamine-
releasing agent contributing to the effects of drugs of abuse is increasing. TYR is 
a trace amine derived from the amino acid tyrosine. It may induce 
vasoconstriction and regulate blood pressure, and is essential for female sperm 
storage, and for larval locomotion in D. melanogaster.66 It is known for having 
moderate psychoactive effects associated with the consumption fermented foods, 




excess consumption, especially in persons concurrently taking an MAOI, can 
have psychoactive sympathomimetic effects.68 Much like OCT, TYR also has 
effects on the adrenergic and dopaminergic systems.69 . It has been suggested 
that TYR may act as a direct agonist of brain DA receptors.69 This makes the role 
of tyramine in amphetamine-induced changes in neurochemistry important to 
examine. No significant differences were observed between WT D. melanogaster 
and N484D mutants in respect to TYR or OCT concentrations in this study.  
Lastly, it was unknown if gender-specific differences would be observed 
amongst drug-treated flies. No differences were observed between male and 













CHAPTER 3. DISCUSSION 
3.1 Discussion of results 
Amphetamines are a class of potent psychoactive drugs that are used for 
both therapeutic and recreational purposes. The pharmacological activity of 
amphetamines is mainly caused by their action on monoamine neurotransmitter 
systems. In particular, a reversal of the transport cycle of the monoamine 
transporters SERT, DAT, and NET leads to increased synaptic concentrations of 
neurotransmitters, and contributes to their psychoactivity.68  
Previous research has shown that dSERT is insensitive to MDMA.51, 70 
However, a dSERT point mutation (N484D) has been identified that restores 
sensitivity to MDMA in vitro. Here, an in vivo analysis of the effects of MDMA and 
METH exposure on biogenic amine levels in wild-type flies and flies expressing 
dSERT N484D was performed. Results showed that treatment with 0.05% 
MDMA significantly reduced 5-HT levels in dSERT N484D flies relative to wild-
type flies. As significant drug-induced changes were not observed in the levels of 
other neurotransmitters investigated, it may be that the effects of this mutation in 
dSERT exclusively influence 5-HT levels. This was particularly clear in 
experiments with MDMA, which has greater affinity for SERT relative to other 
amphetamines.2, 45 Although lower DA content was observed in N484D flies than 
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wild-type flies treated with 0.05% MDMA (figure 2.4 A), this was not the result of 
drug effects (figure 2.3 A, B). 
Previous in vitro work performed in the Barker laboratory show that the 
N484D mutation restores amphetamine-induced efflux to dSERT. Without the 
presence of an acidic residue to create a functional salt bridge between the two 
transmembrane helices, wild-type dSERT exhibits minimal responsiveness to 
amphetamines. When the salt bridge is restored by the mutation of asparagine 
484 to an aspartate this functionality is also reintroduced. The results for 0.05% 
MDMA-treated flies complement this in vitro data from the Barker lab suggesting 
an essential role for this salt bridge in mediating the ability of amphetamines to 
be substrates for SERT, and underline the importance of this specific residue in 
the native function of SERT. However, the lack of a response to 0.6% MDMA and 
0.6% METH was unexpected.  
Though a large number of flies were used (approximately 30 flies per data 
point), no more than 6 data points were generated for any time point, and most 
had only 2 or 3. It may be that significant changes were not observed due to this 
relatively small sample size, potentially skewing the results. Much of the data did 
not show the predicted changes in neurochemistry. However, it is noteworthy that 
where the predicted changes were observed, the trend was for N484D flies to 
have lower neurotransmitter levels than wild-type flies (e.g. figure 2.1 A, B). It 
may be that with a greater number of replicates at each time point more 
conclusive results could be generated. 
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Additionally, this in vivo model used a transgenic targeted expression 
system that inserted dSERT N484D into D. melanogaster without altering native 
dSERT. This may pose a potential limitation to this study, as the presence of 
dSERT may confound the interpretation of results (i.e. a lack of detectable effects 
may be due to native dSERT mitigating drug effects mediated by dSERT N484D). 
The relative abundance of either protein was not assessed, so the extent of 
dSERT involvement was not determined. However, it is important to note that 
although dSERT was present it would still be expected that amphetamines would 
inhibit uptake by dSERT, allowing for neurotransmitter efflux through dSERT 
N484D to lead to drug-induced neurochemical changes. 
 
3.2 Future directions 
The present study examined the role of a conserved acidic residue in SERT 
in vivo by analyzing changes in neurochemistry in D. melanogaster expressing 
the N484D mutant transporter after MDMA or METH exposure. After completing 
these studies, experiments using D. melanogaster tissue for the generation of 
synaptosomes were attempted. Synaptosomes are a useful way to study the 
activity of proteins involved in neurotransmission.71 This could be used to provide 
an alternative means of assessing drug-induced changes in D. melanogaster 
neurochemistry. Synaptosomes are routinely prepared from mammalian tissue 
for laboratory studies. To our knowledge, only one report exists wherein D. 
melanogaster tissue was used for synaptosome generation. 72 Using 
invertebrates rather than mammals for synaptosome preparation requires 
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considerably more samples to yield sufficient quantities of tissue, and is more 
difficult to complete.73 Efforts to make synaptosomes from D. melanogaster have 
thus far been unsuccessful. 
 Additionally, it was observed in these experiments that all flies treated with 
MDMA or METH seemed to respond to treatment in terms of locomotor activity, 
irrespective of whether they were wild-type or N484D. However, this behavior 
was not measured quantitatively. Future behavioral studies would also be useful 
to further understand amphetamine pharmacology and the role of this salt bridge 
in restoring MDMA sensitivity in D. melanogaster. Experiments previously 
performed in the Pittendrigh laboratory using 0.6% METH showed increased 
locomotor activity. It would be predicted that while wild-type flies would not 
respond after MDMA treatment, owing to dSERT insensitivity to MDMA, N484D 
flies would have increased locomotion.  
 Lastly, D. melanogaster has previously been used to study genomic, 
proteomic, and transcriptomic changes after exposure to METH.15 This model 
could also be extended to MDMA to observe systems level changes resulting 
from MDMA-induced 5-HT depletion in N484D flies. Future research using this 
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Table A1.Biogenic amines structures and functions 
 
Biogenic amine Structure Function 
Dopamine 
 
Involved in coordination of movement, reward 
and motivation. Many addictive drugs 
stimulate dopamine release, and this is 




Influences sleep, wakefulness, attention, and 
feeding behavior. Although it is the key 
neurotransmitter in the sympathetic nervous 




Found only in trace amounts in humans. Little 
is known about its function. The main 
neurotransmitter in invertebrates. Replaces 
norepinephrine in the sympathetic nervous 
system.66 Essential for female sperm storage, 
and larval locomotion.67 
Serotonin 
 
Involved in numerous core biological 
functions, including regulation of sleep and 
wakefulness, appetite, and mood.62 
Tyramine 
 
A trace amine which acts as a catecholamine-
releasing agent. May induce vasoconstriction 
and regulate blood pressure. Essential for 
female sperm storage, and for larval 
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